SN
Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
$17.62 -0.11% (-$0.02)
1M -9.96%
Market Cap $1.56B
P/E Ratio -
Div. Yield -
ROE 372.94%
Piotroski F-Score Weak
3/9Valuation
12 /100
Expensive P/S 6.20x
P/B 103.41x
P/E N/A
Growth
0 /100
Declining Book val. growth 48.29%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 97.47%
Net margin 87.60%
FCF margin 87.64%
Quality
5 /100
Poor ROIC 32.12%
ROE 372.94%
Asset turnover 0.36x
Debt
23 /100
High Debt/Equity 39.03x
Current ratio 6.77x
Int. coverage -1.58x
Stability
54 /100
Moderate Beta 0.37x
EPS volatility 20.28%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na SNDX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael A. Metzger
Employees
298
Headquarters
New York City
Nadcházející události
02 LIS
Earnings
Upcoming earnings report